| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Division of Clinical Immunology and Rheumatology, Department of Medicine,
Department of Pathology,
Department of Pharmacology,
Department of Radiation Oncology, and
¶ Department of Microbiology, University of Alabama at Birmingham (UAB), Birmingham, AL 35294; and
|| Birmingham Veterans Administration Medical Center (VAMC), Birmingham, AL 35233
Many tumor cells shed specialized membrane vesicles known as exosomes. In this study, we show that pretreatment of mice with exosomes produced by TS/A or 4T.1 murine mammary tumor cells resulted in accelerated growth of implanted tumor cells in both syngeneic BALB/c mice and nude mice. As implanted TS/A tumor cells grew more rapidly in mice that had been depleted of NK cells, we analyzed the effects of the tumor-derived exosomes on NK cells. The tumor-derived exosomes inhibit NK cell cytotoxic activity ex vivo and in vitro as demonstrated by chromium release assays. The treatment of mice with TS/A tumor exosomes also led to a reduction in the percentages of NK cells, as determined by FACS analysis, in the lungs and spleens. Key features of NK cell activity were inhibited, including release of perforin but not granzyme B, as well as the expression of cyclin D3 and activation of the Jak3-mediated pathways. Human tumor cell lines also were found to produce exosomes that were capable of inhibiting IL-2-stimulated NK cell proliferation. Exosomes produced by dendritic cells or B cells did not. The presentation of tumor Ags by exosomes is under consideration as a cancer vaccine strategy; however, we found that pretreatment of mice with tumor exosomes blunted the protective effect of syngeneic dendritic cells pulsed ex vivo with tumor exosomes. We propose that tumor exosomes contribute to the growth of tumors by blocking IL-2-mediated activation of NK cells and their cytotoxic response to tumor cells.
This article has been cited by other articles:
|
|
 |
|
  I. S. Zeelenberg, M. Ostrowski, S. Krumeich, A. Bobrie, C. Jancic, A. Boissonnas, A. Delcayre, J.-B. Le Pecq, B. Combadiere, S. Amigorena, et al. Targeting Tumor Antigens to Secreted Membrane Vesicles In vivo Induces Efficient Antitumor Immune Responses Cancer Res., February 15, 2008; 68(4): 1228 - 1235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Kim, N. R. Bianco, W. J. Shufesky, A. E. Morelli, and P. D. Robbins MHC Class II+ Exosomes in Plasma Suppress Inflammation in an Antigen-Specific and Fas Ligand/Fas-Dependent Manner J. Immunol., August 15, 2007; 179(4): 2235 - 2241. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Clayton, J. P. Mitchell, J. Court, M. D. Mason, and Z. Tabi Human Tumor-Derived Exosomes Selectively Impair Lymphocyte Responses to Interleukin-2 Cancer Res., August 1, 2007; 67(15): 7458 - 7466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yu, C. Liu, K. Su, J. Wang, Y. Liu, L. Zhang, C. Li, Y. Cong, R. Kimberly, W. E. Grizzle, et al. Tumor Exosomes Inhibit Differentiation of Bone Marrow Dendritic Cells J. Immunol., June 1, 2007; 178(11): 6867 - 6875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Liu, S. Yu, J. Kappes, J. Wang, W. E. Grizzle, K. R. Zinn, and H.-G. Zhang Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host Blood, May 15, 2007; 109(10): 4336 - 4342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. van Niel, I. Porto-Carreiro, S. Simoes, and G. Raposo Exosomes: a common pathway for a specialized function. J. Biochem., July 1, 2006; 140(1): 13 - 21. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
